Weekly shot could replace daily needles for Growth-Hormone deficient kids
NCT ID NCT07260500
First seen Jan 05, 2026 · Last updated Jun 19, 2026 · Updated 24 times
Summary
This study tests a new weekly growth hormone injection (PEG-rhGH) against a standard daily shot in 72 short children born small for gestational age. The goal is to see if the weekly shot works as well or better for increasing height over 26 weeks. Participants are randomly assigned to one of two doses of the weekly drug or the daily drug.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SHORT STATURE CHILDREN BORN SMALL FOR GESTATIONAL AGE (SGA) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology
RECRUITINGWuhan, Hubei, 430030, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
PEGylated recombinant human growth hormone (PEG-rhGH) injection
What this could lead to
If successful, this could offer a once-weekly injection option to help short children born small for gestational age grow taller, potentially reducing the burden of daily shots.
What could go wrong
This is an early phase 2 trial with only 72 participants, so results may not apply to all children. The weekly shot may not work as well as the daily one, and side effects like injection site reactions or growth-related issues are possible.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.